Skip to main content

Advertisement

Table 2 Results of KRAS testing by five CLIA-certified laboratories

From: Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories

Sample ID Clinical Result* Sequencing Lab 1 Sequencing Lab 2 Sequencing Lab 3 Primer Extension Lab 4 Real-time PCR Lab 5
1 WT** WT WT WT WT WT
2 WT WT WT WT WT WT
3 WT WT WT WT WT WT
4 WT WT WT WT WT WT
5 WT WT WT WT WT WT
6 WT WT G12D G12D WT WT
7 G12V G12V G12V G12V G12V G12V
8 G12D G12D G12D G12D G12D G12D
9 G12V G12V G12V G12V G12V G12V
10 G12S G12S G12S G12S G12S G12S
11 G12V G12V G12V G12V G12V G12V
12 G12C G12C G12C G12C G12C G12C
13 G12V G12V G12V G12V G12V G12V
14 G12D WT G12D G12D G12D G12D
15 G13D G13D G13D G13D G13D G13D
16 G13D G13D G13D G13D G13D G13D
17 G13D G13D G13D G13D G13D G13D
18 G13D G13D G13D G13D G13D G13D
19 G13D G13D G13D G13D G13D G13D
20 G13D G13D G13D G13D G13D G13D
  1. *Samples were selected for testing based on these prior clinical results.
  2. **WT: wildtype; G12D: p.Gly12Asp; G12V: p.Gly12Val; G12S: p.Gly12Ser;
  3. G13D: p.Gly13Asp.
  4. This laboratory did see some evidence that the sample had a mutation, but was below the confidence threshold. This specimen showed tumor enrichment of approximately 40%, which is at the lower level of detection for this laboratory.